{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "John Koomen"}, {"accession": "MS:1000589", "name": "contact email", "value": "john.koomen@moffitt.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Moffitt Cancer Center"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Eric Haura, MD"}, {"accession": "MS:1000589", "name": "contact email", "value": "eric.haura@moffitt.org"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Thoracic Oncology"}]}], "datasetFiles": [{"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run1.raw"}, {"accession": "MS:1002848", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run1.raw (F008568).mzid.gz"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run1.raw (F008568).mzid_20200212_Haura_KRAS_celllines_TMT-pY_run1.raw_(F008568).MGF"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run1.raw_(F008568).dta"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run2.raw"}, {"accession": "MS:1002848", "name": "Result file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run2.raw (F008569).mzid.gz"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run2.raw (F008569).mzid_20200212_Haura_KRAS_celllines_TMT-pY_run2.raw_(F008569).MGF"}, {"accession": "MS:1002850", "name": "Peak list file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/20200212_Haura_KRAS_celllines_TMT-pY_run2.raw_(F008569).dta"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/F008568.dat"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604/F008569.dat"}], "description": "Covalent inhibitors of KRASG12C (KRASi) hold considerable progress for tumors driven by this oncogene yet early studies suggest rapid mechanisms of adaptive resistance that appear cell type dependent. To address these challenges, we performed mass spsectrometry baesd phosphoproteomics analysis in KRASG12C cell lines after short term treatment with ARS-1620 and compared phosphoproteomes of KRASG12C cells to understand signaling diversity. Our analysis suggests individual KRASG12C cells responds uniquely to perturbation of KRASG12C.  Cell line models can be categorized in epithelial or mesenchymal subtypes and a similar pattern was observed in KRASG12C human lung cancer tumor tissues. ERBB2/3 signaling compensate for repressed ERK signaling following ARS-1620 treatment in epithelial cell type, and this subtype was also more responsive to inhibition of SHP2, IGFR, and SOS1. Conversely, FGFR signaling drives resistance to KRASi in mesenchymal cells in part via mTOR signaling.  These studies suggest transcriptional subtypes of KRASG12C dictate responsiveness to specific combinations.", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2021/02/PXD021604"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD021604"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD021604"}, {"accession": "MS:1001921", "name": "ProteomeXchange accession number version number", "value": "2"}, {"accession": "MS:1001922", "name": "Digital Object Identifier (DOI)", "value": "10.6019/PXD021604"}], "instruments": [{"accession": "MS:1001911", "name": "Q Exactive"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Lung Cancer, KRAS, phosphoproteomics, mass spectrometry, receptor tyrosine kinases (RTK), targeted therapy, drug resistance, signal transduction"}], "modifications": [{"accession": "MOD:00696", "name": "phosphorylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1002858", "name": "Dataset with its publication pending"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "Cellular States Dictate Adaptive Signaling Responses to KRASG12C Inhibition: Tyrosine Phosphorylation"}